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A quantum leap has been achieved in the last few years in the understanding of the etiology and the pathophysiology of the thrombotic 
microangiopathies (TMA), which includes a spectrum 
of entities like thrombotic thrombocytopenic purpura 
(TTP) and hemolytic uremic syndrome (HUS). TMA 
is characterized by the central feature of endothelial cell 
damage or stimulation due to a myriad of insults, leadt
ing to secretion of long strings of the ultratlarge von 
Willebrand factor (vWF) multimers that remain ant
chored to the cell membrane. These multimeric strings 
are strongly bonded to the glycoprotein Ibα compot
nents of platelet glycoprotein IbαtIXtV surface recept
tors, causing adherence of platelets and the subsequent 
aggregation of additional platelets to each other via act
tivated glycoprotein IIbtIIIa receptors. This produces 
potentially occlusive platelet thrombi, culminating in 
intravascular platelet clumping. 
TTP and HUS usually are pathologically distinct 
diseases with thrombi rich in vWF and platelets occurt
ring in TTP while platelettfibrin rich hyaline thrombi 
occur in diarrheatassociated HUS, suggesting two 
distinct pathways that cause microvascular thrombot
sis. The classic pentad (fever, thrombocytopenia, mit
croangiopathic hemolytic anemia, renal insufficiency, 
and neurologic symptoms) is typical of TTP but seen 
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thrombotic microangiopathies encompass a group of disorders characterized by microangiopathic he-
molytic anemia, thrombocytopenia associated with hyaline thrombi (comprised primarily of platelet ag-
gregates in the microcirculation), and varying degrees of end-organ failure. many primary (genetic) and 
secondary etiological predisposing factors have been described—namely pregnancy, autoimmune disor-
ders, cancer, drugs and antineoplastic therapy, bone marrow transplantation/solid organ transplantation, 
and infections. in the setting of infectious diseases, the association with shiga or shiga-like exotoxin of 
Escherichia coli 0157:h7 or shigella dysenteriae type 1-induced typical hemolytic uremic syndrome is 
well known. recently however, an increasing body of evidence suggests that viruses may also play an 
important role as trigger factors in the pathogenesis of thrombotic microangiopathies. this is a compre-
hensive review focusing on the current understanding of viral associated/induced endothelial stimulation 
and damage that ultimately leads to the development of this life-threatening multisystemic disorder.
only in 1/3 of patients. In HUS most patients do not 
have widetspread systemic symptoms and hematologic 
complications, but predominately renal involvement. 
TTP can be subdivided into three types: congenital or 
familial, idiopathic, and nontidiopathic. The congenital 
and idiopathic TTP syndromes are caused primarily 
by deficiency of ADAMTS13, owing to mutations in 
the ADAMTS13 gene or autoantibodies that inhibit 
ADAMTS13 activity. Nonidiopathic secondary TTP 
is associated with conditions like autoimmune diseases 
and vasculitis (systemic lupus erythematosus, sclerot
derma) pregnancy/postpartum; cancer; hematopietic 
stem cell transplantation, drugs and other antineot
plasic agents (gemcitabine, mitomycin C, calcineurin 
inhibitors, quinine, cocaine, ticlopidine, clopidogrel) 
and infections. HUS may be classified as either diart
rheatassociated (due to enteric infection with Shigat
toxintproducing organisms) or nontdiarrhea/atypical 
(aHUS). aHUS has recently been shown to be a dist
ease of complement dysregulation, with 50% of cases 
involving the complement regulatory genes, factor 
H, membrane cofactor protein (MCP/CD46), fact
tor I and factor B. However, incomplete penetrance 
of mutations in ADAMTS13 or complement regulat
tory genes strongly supports that precipitating events 
or triggers are necessary to cause endothelial damage, 
review VIRAL-ASSOCIATED THROMBOTIC MICROANGIOPATHIES
Hematol Oncol Stem Cell Ther 4(2)     Second Quarter 2011 hemoncstem.edmgr.com52
which evolves to thrombotic microangiopathy in many 
patients. Recently, mutations in the thrombomodulin 
gene and a newly described mechanism of inactivation 
of protangiogenic vascular endothelial growth factor 
(VEGF) or its signalling mechanisms like the recept
tort1 tyrosine kinase signalling mechanism secondary 
to some drugs (bevacizumab, sunitinib) could promote 
the formation of intratarterial platelet aggregation and 
is therefore a strong risk factor for the development of 
TMA (Table 1).1t23
The main focus of this review is to emphasize and 
raise clinician awareness of the contribution of many 
types of viruses to endothelial damage, which ultit
mately leads to the cascade of events culminating in the 
manifestations of TMA. Multiple viral agents have the 
capability to induce stimulation of endothelial cells or 
activation of alternative pathways either alone or synt
ergistically with other cotfactors that result in TMA. 
An overview of the types of viruses and the proposed 
pathophysiologic mechanisms are summarized below 
(Table 2).  
RNA viruses
Retroviridae family-related TMA
Retroviruses are enveloped viruses that belong to the 
viral family Retroviridae. A retrovirus is an RNA virus 
that is replicated in a host cell via the enzyme reverse 
transcriptase to produce DNA from its RNA genome. 
The DNA is then incorporated into the host’s genome 
by an integrase enzyme. The virus thereafter replicates 
as part of the host cell’s DNA. Two viruses from this 
family have been associated with TMA. 
Increasingly recognized is TMA associated with the 
human immunodeficiency virus (HIV) infection, which 
is the most extensively studied and reported. HIV is a 
member of the genus Lentivirus, part of the family of 
Retroviridae. Over two hundred cases of HIV related 
TMA or TMAtlike syndrome have been reported so 
far. A detailed review of HIVtrelated TMA has been 
discussed elsewhere so this review will focus only on the 
most important aspects.24t26 
Both TTP and HUS are associated with HIV int
fection. Although in the HIV setting TMA occurs 
in the later stages of infection, there are reports of 
TMA as a primary manifestation of acute viral infect
tion.27 TMA is more common in HIVtinfected indit
viduals than in the normal population. Lower CD4+ 
cell counts (<100/uL), higher HIVt1 RNA levels, 
clinical AIDS, opportunistic infections (e.g., CMV 
or HHVt8 infection), various drugs commonly used 
in advanced disease, and immune reconstitution after 
response to combined antiretroviral therapy (cART) 
are all considered to be potential HIVtrelated risk 
factors.28t32 Multiple mechanisms have been prot
posed for the pathophysiology of HIVtrelated TMA. 
Complete deficiency of the vWF–cleaving protease 
ADAMTS13 has been reported in HIVtassociated 
TTP due to development of IgG and occasionally IgA 
and IgM autoantibodies. There is a contrary argument 
also, that in HIVtassociated TMA, the metalloprot
teinase levels are generally not decreased, and that an 
alternative mechanism is responsible for a different 
pathophysiology than the idiopathic form of TTP.33t36 
Demonstration of the virus p24 antigen in the endot
thelial cell suggests either a direct cytopathic effect of 
the virus or functional impairment of the endothet
lium; in another report, specific viral envelope mutat
tions were found in a region known to influence viral 
endothelial tropism.37,38 
In idiopathic TMA, patients who undergo plasmat
pheresis with or without prednisone have a decrease in 
mortality rate from almost 100% to 10%. Patients with 
HIVtassociated TMA, who do not have AIDS, have a 
similar favorable outcome when treated with plasmat
pheresis. Recently, some reports have shown the efficacy 
of monoclonal antibodies to HIVtTMA refractory to 
plasma exchange.39,40 While HIVtassociated TMA has 
a good prognosis, similar to that of idiopathic TMA, 
AIDStassociated TMA has a very poor prognosis. The 
etiology of the higher mortality in AIDStassociated 
TMA as compared to HIVtassociated TMA remains 
unclear, but a higher viral burden and HIVtrelated sect
Table 1. Summary of the etiology  of thrombotic thrombocytopenic purpura (TTP), 
hemolytic uremic syndrome (HUS) and atypical hemolytic uremic syndrome (aHUS).
Etiology
TTP
    Congenital/Familial Mutations in ADAMTS13 gene
    Idiophatic Antibodies anti-ADAMTS13
    Non-idiophatic Vasculitis, pregnancy, cancer, drugs,solid organ/stem cell transplantation, infections
HUS
Shiga-toxin-producing organisms 
(Escherichia coli 0157:H7)
aHUS 
     50% cases Mutations in alternative complement pathway regulatory genes; antibodies anti-complement
     Remaining cases
Upper respiratory tract infections, gastroenteritis; 
medications; systemic diseases; malignancy, pregnancy; 
Inactivation of VEGF and downstream signalling 
pathway; mutations in thrombomodulin gene; other 
mechanisms?
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ondary complications like opportunistic infections and 
cancer are considered to be strong contributors. In the 
later stages of HIV disease, there is a high risk of death 
from TMA at 1 year (31%t38%), with a significant 
morbidity and mortality and very poor survival (45% of 
AIDS patients die within 2 months of virus detection).
HIV patients with HUS present with more severe 
immunologic deterioration than patients with TTP. 
Although initial clinical symptoms are fewer than TTP, 
diagnosing HUS implicates a very poor prognosis with 
life expectancy rarely exceeding 1 year. With the advent 
of the era of combined antiretroviral treatment (cART), 
a visible decline in the incidence of HIVtTMA to valt
ues well below 1% of HIVtinfected patients has been 
observed. A high response rate is reported to plasma int
fusion and antitretroviral therapy, reducing the need for 
plasma exchange in treating this complication. This may 
be due to the reported lower incidence of opportunistic 
infections and AIDS related tumors.28t32
A point of caution for the clinician is that diagnot
sis of TMA in HIV patients is tricky. The presence of 
microangiopathic hemolytic anemia and thrombocytot
penia with no underlying cause is nontspecific. Because 
AIDStrelated disorders may cause these abnormalities, 
the diagnosis of TMA is often uncertain in patients 
with HIV infection.
The HTLVt1 is a human RNA retrovirus from the 
genus Deltaretrovirus and member of the Retroviridae 
family that causes Ttcell leukemia and Ttcell lymphot
ma in adults and may also be involved in certain demyt
elinating diseases, including tropical spastic paraparesis. 
To date, only 5 cases of HTLVt1, which responded to 
plasma exchange or infusion were described as being 
the causative agent of TTP in previous healthy pert
sons. This suggests that the mechanism of viraltinduced 
TMA is also through the ADAMTS13 function.41,42
Flaviviridae family-related TMA
The hepatitis C virus (HCV) is a small (50 nm in size), 
enveloped, singletstranded, positive sense RNA virus. 
It is the only known member of the Hepacivirus genus 
in the family Flaviviridae. Anticardiolipin antibodies 
(ACA) have been linked with chronic HCV infection. 
Renal TMA occurring in HCV positive renal allograft 
recipients with a positive ACA test has been recently ret
ported.43 ADAMTS13 inhibition was also described as 
a mechanism of HCVtrelated TMA.44 However, most 
reports show that HCV antitviral treatment (interfert
on and peguylated ribavirin) as well as living donor liver 
transplantation in patients with endtstage liver disease 
due to HCV infection by themselves are responsible for 
the pathogenesis of TMA.45t52 
Table 2. Overview of the suspected mechanism of pathogenesis of viral TMA.
Virus Type of TMA Mechanism of pathogenesis
RNA viruses   
  Retroviridae family   
      HIV TTP/HUS
- Direct endothelial injury
- ADAMTS13 deficiency?
-Other mechanisms?
      HTLV-1 TTP - ADAMTS13 inhibitors
  Flaviviridae family   
      Hepatitis C TTP - Anticardiolipin antibodies- ADAMTS13 inhibitors
      Dengue TTP
- Direct endothelial injury
- ADAMTS13 inhibitors
- Immune complex mediated
  Reoviridae family   
      Rotavirus HUS -Unknown
  Caliciviridae family   
      Norovirus HUS -Unknown
  Bunyaviridae family   
      Crimean-Congo 
      fever virus TTP -Cytokine storm-mediated endothelial injury
  Picornaviridae  family   
      Hepatitis A HUS - Unknown
      Coxsackie; Echovirus HUS - Direct endothelial injury
  Orthomyxoviridae 
  family   
      Influenza A TTP/HUS/aHUS
- ADAMTS13 inhibitors
- Complement dysfunction
DNA viruses   
  Herpesviridae  family   
      Varicella-zoster 
      virus aHUS.
- Direct endothelial injury
- Complement dysfunction
      CMV TTP/HUS -Direct endothelial injury-Cytokine storm-mediated endothelial injury
      HHV-6 TTP -Direct endothelial injury-Cytokine storm endothelial injury
      EBV HUS -Unknown
      HHV-8 TTP -Direct endothelial injury
  Adenoviridae family   
      Adenovirus TTP/HUS
-Modulation of endothelial intracellular 
  factors
- NK cytotoxicity
  Parvoviridae family   
      Parvoviris B19 TTP/HUS - Direct endothelial injury- Immune-complex mediated
  Polyomaviridae family    
      BK virus TTP   - Direct endothelial injury
TTP: thrombotic thrombocytopenic purpura; HUS-hemolytic uremic syndrome; aHUS: atypical HUS; HIV-human 
immunodeficiency virus; HTLV-1: human lymphotropic lymphoma virus-1; CMV: cytomegalovirus; HHV-6: human 
herpes virus-6; EBV: Epstein-Barr virus; HHV-8: human herpes virus-8
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East and West Africa, belongs to the genus Naiovirus 
and is a member of the Bunyaviridae family of RNA 
viruses. One report showed the association of this int
fection in a patient that presented with a fatal fulminant 
picture of TTP. A positive molecular testing for CCHF 
virus was reported. Several features of that case suggest 
a cytokinetmediated mechanism for the pathogenesis of 
CCHF infection.58
Picornaviridae family-related TMA
Hepatitis A virus, from the Hepatovirus genus and 
Picornaviridae family was described in a single report as 
the trigger factor for HUS without other recognizable 
causative etiologic agents.59 No other cases have been 
described so far since hepatitis A infection is generally a 
selftlimited disease. 
Coxsackievirus, Echovirus
Sporadic cases of HUS with coxsackie and echovirus 
were reported in the literature in children and adolest
cents. The first was reported in 1965, in which coxt
sackievirus A was isolated from a patient with typical 
HUS and without other precipitating causal factors.60 
Subsequently, in 1971, a case of a child with myocart
ditis due to coxsackievirus B infection and concomit
tant development of the clinical picture of HUS was 
reported.61 Similar cases were later reported.62,63 A ret
view of the records of 21 children with HUS seen bet
tween 1967 and 1972 revealed a tendency for cases to 
occur predominantly during the late summer months. 
Nineteen of these children were studied serologically 
for evidence of associated infection with coxsackie B vit
ruses, and evidence was found in 15 (79%) of these pat
tients. Coxsackie B viruses were isolated concomitantly 
from two of the patients.62,63
Echovirus type 22 is another enterovirus with a 
strong association with HUS in pediatric patients. 
Eight among 10 patients with HUS had a recent epit
sode of a proved gastroenteritis due to Echovirus 22 
according to one study.64 Concurrent infection with 
two or more enteroviruses was described in a cluster of 
10 family cases with recent gastroenteritis followed by 
HUS. This suggests that the various enteroviruses can 
act synergistically to promote HUS development.65 It 
is known that coxsackie B viruses can attack vascular 
endothelium, and if disruption of the endothelium oct
curs, it is possible that vesseltwall collagen could act
tivate platelets and result in intravascular coagulation. 
The demonstration of coxsackie B4 antigen in the renal 
tissue supports a direct viral effect.65,66
The possible TMA etiological role of the enterovit
rus (coxsackie virus and echovirus) was questioned in 
Dengue virus is a single positivetstranded RNA vit
rus of the family Flaviviridae; genus Flavivirus and infect
tion by this virus also appears to be a contributing fact
tor for TMA. In a reported case, renal biopsy showed 
TMA with glomerular and arteriolar microthrombi and 
electron microscopy revealed the presence of microtut
buloreticular structures, suggesting a viral infection. The 
glomerular changes observed in dengue hemorrhagic fet
ver have only been scarcely described and can include a 
variety of signs, including IgG, IgM, and/or C3 deposit
tion and thickening of the glomerular basal membrane.53 
Acquired IgG ADAMTS13 inhibitor during the acute 
phase of dengue virus infection was recently demont
strated. An excellent response to plasma exchange and 
disappearance of the antitADAMTS13 inhibitor after 
remission of TMA and dengue resolution was seen in 
that report.54
Reoviridae family-related TMA
Rotavirus is a genus of doubletstranded RNA virus in 
the family Reoviridae and is the most common cause 
of severe diarrhea among infants and young children. 
Only one case to date of a possible relationship of this 
virus and TMA was reported in an elderly patient. The 
presence of the rotavirus in the fecal matter, the absence 
of other TMA causative factors and the favorable clinit
cal course after viral disappearance favored a causal role 
in the pathogenesis of TMA.55 However, caution is 
advised for the risk of false positives in stool samples 
analysis so other diagnostic techniques must be used to 
confirm the suspected diagnosis.56
Caliciviridae family-related TMA
Norovirus (formerly Norwalk agent) is an RNA virus 
member of the Caliciviridae family that causes approxit
mately 90% of nontbacterial outbreaks of gastroenterit
tis around the world. Only a single case of HUS comt
plicated with norovirustassociated gastroenteritis has 
been reported so far.57 It is unclear as to whether the 
patient’s norovirus infection was a root cause, a simple 
coincidence, or a precipitating factor for HUS since the 
patient had chronic kidney disease and hypertension. 
Further accumulation of clinical studies including case 
reports is necessary to confirm whether HUS is a real 
association in patients with norovirustassociated gast
troenteritis.
Bunyaviridae family-related TMA
CrimeantCongo hemorrhagic fever (CCHF) virus is a 
widespread ticktborne viral disease, a zoonosis of dot
mestic animals and wild animals, that may affect hut
mans. The pathologenic virus, especially common in 
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a study where investigators stated that verocytotoxint
producing Escherichia coli (VTEC) infection causes 
most cases of HUS. Ten to 30% of patients, however, 
are negative for VTEC infection. The etiology of HUS 
in VTECtnegative cases remains poorly understood. 
The frequency of enteroviral infections was not statistit
cally significant in the acute phase of VTECtpositive 
and VTECtnegative HUS. Therefore, enteroviral int
fections should not be considered a cause of HUS in 
VTECtnegative children.67 Although this may be argut
able, a patient with HUS and gastroenteritis secondary 
to enteroviruses strongly supports the viral role in the 
triggering of the cascade that culminates in TMA.
Orthomyxoviridae family-related TMA
Influenza A virus is an RNA virus, the sole member 
of the genus Influenzavirus A, which belongs to the 
broader family of Orthomyxoviridae. TMA secondt
ary or induced by influenza A virus infection has been 
reported several times during the recent pandemic of 
H1N1 influenza A infection. The proposed pathophyst
iology of TMA includes in one case the production of 
antitADAMTS13 inhibitors of the IgG type, which 
produced a clinical picture of TTP that was fatal even 
after steroid administration and plasma exchange.68 
Interestingly, there are also three reports showing that 
inactivated human influenza vaccine may induce TTP 
bouts by boosting the production of antitADAMTS13 
autoantibodies.69t71
H1N1 and also H1N1tassociated bacterial int
fections have to be considered in HUS and aHUS 
patients: In a report, aHUS in a patient with a mutat
tion in the gene (CD46) encoding the transmembrane 
complement regulator membrane cofactor protein was 
triggered by H1N1 infection and had a good outcome 
with oseltamivir, plasma exchange and hemodialysis. 
Two other cases of aHUS were apparently triggered by 
this virus.72t74 Although H1N1 influenza A virus may 
have been the trigger of aHUS in the cases reported 
here, it remains an interesting but unanswered question 
whether an underlying complement defect served as a 
susceptibility factor, at least in a subgroup of patients.75 
Cotinfection with influenza A virus and the bacteria 
Streptococcus pneumoniae may act synergistically to int
duce HUS via neuraminidase activity since both agents 
alone were shown to be associated with this clinical pict
ture. The neuraminidase of influenza may even cause 
erythrocyte fusion and hemolysis.76t78 Another case 
was described as a late complication of a renal allograft 
patient with clinical and laboratorial manifestations of 
HUS. Although immunosuppressive drugs were ruled 
out as the direct causative agent of HUS since the mant
ifestations occurred concomitantly with an influenza 
virus infection, the exact mechanism of lesions was not 
characterized.79,80
DNA viruses
The Herpesviridae are a large family of DNA viruses 
composed of relatively large doubletstranded, linear 
DNA genomes encoding 100t200 genes encased witht
in an icosahedral protein cage called the capsid, which 
is itself wrapped in a protein layer called the tegument 
containing both viral proteins and viral mRNAs and a 
lipid bilayer membrane called the envelope. This family 
of DNA viruses are divided into subfamilies:
Alpha-herpes virus subfamily
Only one case of typical HUS complicating varicellat
zoster virus (VZV) (Human herpesvirus 3) infection 
was reported so far with autopsy showing diffuse capt
illary wall thickening and extensive wrinkling of the 
glomeruli basement membrane with subendothelial 
deposition of granular material.81 A second report of 
two cases of aHUS after VZV infection, with comt
plement dysfunction, one of them having a membrane 
cofactor protein mutation, and the other antitfactor 
H antibodies shows that infectious agents such as 
VZV may be the trigger of aHUS in patients with 
complement dysregulation and should lead to extent
sive screening of the complement system in order to 
identify susceptibility factors.82
Beta-herpes virus subfamily
Cytomegalovirus (CMV) (Human herpesvirus 5) 
infection or reactivation can initiate endothelial int
flammation and vasculitis and play a causative role in 
TMA, resulting in both TTP or HUS clinical manit
festations. CMV can directly damage the endothelial 
cells and can cause platelet adhesion to the microvast
cular wall by inducing the expression of endothelial 
adhesion molecules and the release of vWF. In fact, 
vascular endothelial CMV infection can be detected 
in about 50% of patients who develop TMA secondt
ary to HIV infection and CMV is very frequently 
found in patients with AIDS at autopsy since CMV 
inclusions were detected in kidney specimens obt
tained from HIVtinfected patients with TMA sugt
gesting that cotinfection with both virus may promote 
TMA genesis.83t89 CMV infection and TMA in the 
transplant setting (bone marrow/solid organ transt
plantation) may also occur. One case of CMVtassot
ciated TMA after liver transplantation was reported 
and resolved after antitviral therapy. In renal allograft 
recipients, CMV can cause distinctive glomerulopathy 
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medication and aspirin, resolved the clinical picture.102 
In the third case the clinical course was uneventful with 
mild HUS manifestations.103 The rarity of EBVtrelated 
TMA probably stems from the absence of CD21 antit
gen on the glomerular endothelial cells which is the celt
lular receptor for EBV, implying that other mechanisms 
besides a direct cytopathic effect is responsible for the 
endothelial damage that leads to TMA. 104
Human herpesvirus 8 (HHVt8) infection (Kaposi 
sarcomatassociated herpesvirus), which is common 
among advanced stage disease HIVtinfected patients, 
involves vascular endothelial cells and may contribute 
to the development of TMA by direct endothelial int
jury or stimulation and thus potentiating the effects of 
HIVtrelated TMA.105 
Adenoviridae family-related TMA
 Adenoviruses are mediumtsized (90–100 nm), nonenvelt
oped icosahedral viruses composed of a nucleocapsid and 
a doubletstranded linear DNA genome and are members 
of the Adenoviridae family. There are 55 described serot
types in humans, which are responsible for 5% to 10% of 
upper respiratory infections in children, and many infect
tions in adults as well. Adenoviruses are increasingly rect
ognized as a significant cause of morbidity and mortality 
in immunocompromised patients. Disseminated adenot
viral disease has been associated with fatal cases of TTP 
and HUS, one after allogeneic bone marrow transplantat
tion and another in an AIDS patient with disseminated 
adenovirus and cytomegalovirus cotinfection, respect
tively. The proposed mechanism of adenovirus induced 
endothelial damage may be modulation of expression 
of endothelial intracellular factors that increase natural 
killer celltmediated cytotoxicity. 88,106,107
Parvoviridae family-related TMA
 Parvovirus B19 (Human parvovirus B19), an erythrot
virus member of the Parvoviridae family of small DNA 
viruses, is a nontenveloped, icosahedral virus that cont
tains a singletstranded linear DNA genome and is the 
etiologic agent of aplastic anemia. TTP and HUS were 
associated with parvovirus B19 infection both in imt
munocompetent and immunosuppressed individuals. 
Supertinfection of this virus in a HUS patient with E 
coli 0157:H7 may amplify the clinical and laboratory 
manifestations. TMAtrelated parvovirus B19 infect
tion developing after renal transplantation was demont
strated by a typical clinical picture allied by a positive 
polymerase chain reaction amplification of viral DNA 
in the renal biopsy specimens along with positive IgM 
serology and profound reticulocytopenia. Parvovirus 
B19trelated TMA may also precede allograft vasculitis 
characterized by endothelial damage and mononuclet
ar cell infiltration of glomerular capillaries. Infection 
with CMV as a trigger for posttransplant TMA in 
renal allografts has been reported in 8 cases. All pat
tients developed TMA between 4 weeks and 25 years 
after transplantation. Although in all these cases, the 
coexistence of multiple factors (transplant, grafttvert
susthost disease, immunosuppressive drugs) may have 
contributed to the clinical picture of TMA, the course 
of disease with onset of TMA within days after onset 
of CMV disease and the disappearance of hemolysis 
after negativation of CMVtDNAemia is highly sugt
gestive of a causative role of CMV in the developt
ment of posttransplant TMA. Moreover in one case 
it is highly unlikely that the TMA would have been 
induced by the immunosuppression since renal transt
plantation was done 25 years ago and all evidence int
dicates a CMVtinduced TMA. Resolution of TMA 
after CMV treatment in all these cases, reinforces the 
notion that CMV infection is an important contributt
ing factor for TMA development. 90t96
Human herpesvirus 6 (HHVt6), which is closely ret
lated to CMV, is known to infect lymphocytes, monot
cytes/macrophages, and vascular endothelial cells. It 
has also been suggested as a potential cause of TMA, 
leading to activation and damage of endothelial cells 
more severely than CMV and increased thrombot
modulin, and plasminogen activator inhibitort1 levels. 
Cotinfection with both viruses amplifies endothelial 
injury. Elevation of cytokine levels both in CMV and 
HHVt6 infection has been associated with endot
thelial damage and TMA. HHVt6 infection usually 
reactivates during immunosuppression due to hight
dose chemotherapy in conditioning regimens of bone 
marrow transplantation. HHVt6trelated TMA is an 
underdiagnosed entity. However, given its rapid lethal 
course if left untreated and owing to its good response 
to antiviral therapy the clinician must stay alert for this 
association and act promptly on minimal clinical and 
laboratory suspicion.97t100 
Gama herpes virus subfamily
HUS associated EpsteintBarr virus/Human herpesvir
rus 4 (EBV/HHVt4) was first reported in 1974. Since 
then, only two more cases have been reported. In the 
first case EBV developed into thrombocytopenia with 
HUS during the convalescent phase as an unusual mant
ifestation.101 In the second reported case, in a patient 
with HUS developing in the context of a infectious 
mononucleosis with positive IgMtEBV VCA antibody 
and EpsteintBarr nuclear antigen, supportive care int
cluding hemodialysis, plasmapheresis, antihypertensive 
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in renal transplant recipients. The temporal association 
between aplastic anemia and the onset of thrombotic 
graft microangiopathy, isolation of the viral genome in 
renal specimens, seroconversion, endothelial tropism 
of the virus (the receptor for parvovirus B19 on erytht
rocytes, the P antigen, is also present on endothelial 
cells) and possibly production of circulating immune 
complexes suggest that parvovirus B19 could be the 
etiologic agent of TMA in these cases. A high index of 
suspicion is required for early diagnosis and treatment 
of parvovirus Bt19 infection.108t114
Polyomaviridae family-related TMA
BK virus (BKV), a doubletstranded DNA virus, is a 
member of the Polyomaviridae family. BKVtrelated 
TMA was recently described for the first time in an 
allogeneic hematopoietic stem cell transplant patient, 
in whom the disease developed many years after the 
procedure as a proved BKV encephalitis that was 
complicated by a fulminant clinical picture of TTP.
Although many factors may have triggered the TMA 
(grafttversusthost disease, calcineurin inhibitors), ult
timately BKV infection appeared to be the precipitatt
ing factor in a susceptible host in this case. BKV has 
also been associated with a fatal case of vasculopathy 
in a renal allograft patient, in which disseminated ent
dothelial infection by BKV was proved.116 BKV may 
have a direct cytopathic effect in endothelial injury, 
but other mechanisms may be responsible for the 
pathogenesis of TMA in this type of infection. More 
cases are needed to confirm this and the clinician 
must be aware of this association.  
Conclusions
Viruses are important etiologic agents in the pathogent
esis of TMA.117,118 Some have a propensity to induce 
TTP while others are only associated with HUS or 
aHUS. The exact pathophysiology of viraltassociated 
TMA remains to be elucidated. However, direct endot
thelial cell injury appears to play an important role. Host 
genetic or ambient susceptibility factors may create a 
favorable ground for the viruses to trigger the cascade 
of events that culminates in the clinical manifestations 
of TMA. Although some claims of viraltrelated TMA 
appear only in anecdotal reports, one cannot reject the 
possibility of such associations. More cases must be ret
ported to consolidate and reinforce the causal relationt
ship in such circumstances. Clinician awareness is vital 
when TMA occurs in the context of a viral infection in 
the absence or even in the presence of confounding init
tiating factors, since prompt recognition of the clinical 
picture may be lifetsaving. 
The author declares no conflict of interest.
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